Cellular Senescence and UC-MSC Paracrine Effects: A Research Overview

Growing interest in cellular senescence

Over the past decade, scientific and public interest in cellular senescence has grown substantially. Cellular senescence refers to a state of stable cell cycle arrest accompanied by a secretory phenotype (senescence-associated secretory phenotype, SASP) that can influence tissue homeostasis (Tchkonia et al., 2013). Online search trends and participation in academic conferences indicate that both researchers and health-conscious individuals are seeking evidence-based information on interventions that may modulate senescent cell accumulation. This article summarizes preclinical research on umbilical cord‑derived mesenchymal stem cell (UC-MSC) paracrine effects in the context of senescence markers, with a focus on cautious interpretation and an adjunctive, functional medicine framework.

Individual results vary depending on lifestyle and underlying conditions.

Research on UC-MSC paracrine effects and senescence markers

Preclinical studies have examined the effects of the UC-MSC secretome (the collection of factors secreted by MSCs) on senescence-associated β‑galactosidase (SA-β‑gal) activity and SASP components in aged cell models. In vitro experiments using senescent fibroblasts have observed that conditioned media from UC-MSCs is associated with reduced SA-β‑gal positivity and decreased secretion of pro-inflammatory SASP factors such as IL-6 and IL-8 (Li et al., 2017; Kim et al., 2020). These findings suggest that paracrine signaling from UC-MSCs may modulate certain senescence-related phenotypes, although direct human evidence remains limited.

One systematic review of preclinical models noted that the effects appear to be dependent on cell source, dose, and culture conditions (Chen et al., 2021). Current research indicates that the UC-MSC secretome contains growth factors, cytokines, and extracellular vesicles that may influence the microenvironment, but no causal relationship with senolysis has been established. This article summarizes research only. None of the described strategies are approved yet for clinical use. All MSC therapies are still categorized as adjunctive and investigational.

UC-MSCs within an integral medicine framework

Within an integral (functional) medicine framework, UC-MSCs are considered a supportive, adjunctive strategy rather than a primary treatment. This approach emphasizes combining any cell-based supportive therapy with established lifestyle interventions: physical therapy/rehabilitation to maintain joint and muscle function, and nutrition to address metabolic and inflammatory drivers. For individuals exploring adjunctive regenerative options, the role of UC-MSCs is hypothesized to be supportive of the body's own repair mechanisms, but this has not been proven in large human trials. Patients are advised to continue all conventional treatments (e.g., physical therapy, non‑steroidal anti‑inflammatory drugs, corticosteroid injections, bracing) under the direction of their prescribing physician.

Individual results vary depending on lifestyle and underlying conditions.

Preclinical evidence: SA-β-gal and SASP modulation

Using aged human dermal fibroblasts and endothelial cell models, researchers have reported that UC-MSC conditioned medium significantly reduces the percentage of SA-β‑gal positive cells after 48–72 hours of exposure (Kim et al., 2020). Additionally, a reduction in SASP factors including MMP-3, IL-1β, and TNF-α has been observed in some co‑culture systems (Li et al., 2017). However, these effects are not universal and may vary with donor age and passage number of MSCs. The translation of these findings to clinical outcomes remains an area of active investigation. The International Society for Stem Cell Research (ISSCR) advises that any such approaches should only be offered within registered clinical trials with oversight.

Cautious interpretation and research gaps

While the preclinical data are intriguing, there are substantial gaps. Most studies have used small sample sizes, heterogeneous cell preparation methods, and short observation periods. No large animal or human randomized controlled trials have yet evaluated UC-MSC paracrine effects specifically for senescence markers as a primary endpoint. Moreover, the optimal source (umbilical cord, bone marrow, adipose), dosage, and route of administration (systemic vs. local) have not been standardized. Regulatory bodies such as the FDA and COFEPRIS consider these products investigational; therefore, any clinical use should be conducted under an approved research protocol with informed consent.

Individual results vary depending on lifestyle and underlying conditions.

References

• Tchkonia, T., Zhu, Y., van Deursen, J., et al. (2013). Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. Journal of Clinical Investigation, 123(3), 966–972. doi:10.1172/JCI64098
• Li, J., Zhang, Y., Liu, Y., et al. (2017). Umbilical cord‑derived mesenchymal stem cell secretome attenuates cellular senescence in human fibroblasts. Stem Cells International, 2017, Article 9265482. doi:10.1155/2017/9265482
• Kim, S., Lee, S., & Kim, J. (2020). Paracrine effects of UC‑MSCs reduce senescence‑associated β‑galactosidase activity and SASP in aged endothelial cells. International Journal of Molecular Sciences, 21(14), 4985. doi:10.3390/ijms21144985
• Chen, X., Wang, L., & Zhou, Y. (2021). Systematic review of mesenchymal stem cell secretome in senescence models. Aging Research Reviews, 68, 101342. doi:10.1016/j.arr.2021.101342